Summary of Study ST003922

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002455. The data can be accessed directly via it's Project DOI: 10.21228/M89G1W This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003922
Study TitleTime-series metabolomic profiling of SARS-CoV-2 infection: Possible prognostic biomarkers in patients in the ICU by ¹H-NMR analysis
Study SummaryThe global impact of SARS-CoV-2, which causes COVID-19, remains significant, being intensified by the emergence of variants. Comprehensive metabolomic studies aimed to elucidate the distinctive metabolic footprint of the virus. For critically ill patients with COVID-19 in the intensive care unit (ICU), longitudinal monitoring based on their prognosis is crucial to optimize treatment outcomes. Methods: This study retrospectively investigated the temporal changes in the metabolomic profiles of patients admitted to the ICU with COVID-19, who were categorized into three prognostic groups: healthy discharged (HD), polyneuropathic syndrome (PS), and Exitus. In total, 32 serum samples collected in April 2020 at regular intervals (four samples per patient) and stored at −80°C, were analyzed using proton nuclear magnetic resonance (1H-NMR) spectroscopy.
Institute
Acibadem University
Last NameBaykal
First NameAhmet
Addressİçerenköy, Kayışdağı Cd. No:32 Atasehir, Istanbul, NA, 34752, Turkey
Emailatbaykal@gmail.com
Phone+902165004828
Submit Date2025-05-20
Raw Data AvailableYes
Raw Data File Type(s)fid
Analysis Type DetailNMR
Release Date2025-06-17
Release Version1
Ahmet Baykal Ahmet Baykal
https://dx.doi.org/10.21228/M89G1W
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR002455
Project DOI:doi: 10.21228/M89G1W
Project Title:Time-series metabolomic profiling of SARS-CoV-2 infection
Project Summary:The global impact of SARS-CoV-2, which causes COVID-19, remains significant, being intensified by the emergence of variants. Comprehensive metabolomic studies aimed to elucidate the distinctive metabolic footprint of the virus. For critically ill patients with COVID-19 in the intensive care unit (ICU), longitudinal monitoring based on their prognosis is crucial to optimize treatment outcomes. Methods: This study retrospectively investigated the temporal changes in the metabolomic profiles of patients admitted to the ICU with COVID-19, who were categorized into three prognostic groups: healthy discharged (HD), polyneuropathic syndrome (PS), and Exitus. In total, 32 serum samples collected in April 2020 at regular intervals (four samples per patient) and stored at −80°C, were analyzed using proton nuclear magnetic resonance (1H-NMR) spectroscopy.
Institute:Acibadem University
Department:School of Medicine- Department of Medical Biochemistry
Last Name:Baykal
First Name:Ahmet
Address:İçerenköy, Kayışdağı Cd. No:32 Atasehir, Istanbul, NA, 34752, Turkey
Email:atbaykal@gmail.com
Phone:+902165004828
Contributors:Emir Matpan, Ahmet Tarık Baykal, Lütfi Telci, Türker Kundak and Mustafa Serteser

Subject:

Subject ID:SU004057
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample source Sample collection time Prognostic group
SA444301S8T0Serum T0 Exitus
SA444302S7T0Serum T0 Exitus
SA444303S3T0Serum T0 Healthy discharged
SA444304S4T0Serum T0 Healthy discharged
SA444305S1T0Serum T0 Healthy discharged
SA444306S2T0Serum T0 Healthy discharged
SA444307S5T0Serum T0 Polyneuropathic syndrome
SA444308S6T0Serum T0 Polyneuropathic syndrome
SA444309S8T1Serum T1 Exitus
SA444310S7T1Serum T1 Exitus
SA444311S2T1Serum T1 Healthy discharged
SA444312S3T1Serum T1 Healthy discharged
SA444313S4T1Serum T1 Healthy discharged
SA444314S1T1Serum T1 Healthy discharged
SA444315S5T1Serum T1 Polyneuropathic syndrome
SA444316S6T1Serum T1 Polyneuropathic syndrome
SA444317S8T2Serum T2 Exitus
SA444318S7T2Serum T2 Exitus
SA444319S1T2Serum T2 Healthy discharged
SA444320S2T2Serum T2 Healthy discharged
SA444321S4T2Serum T2 Healthy discharged
SA444322S3T2Serum T2 Healthy discharged
SA444323S6T2Serum T2 Polyneuropathic syndrome
SA444324S5T2Serum T2 Polyneuropathic syndrome
SA444325S7T3Serum T3 Exitus
SA444326S8T3Serum T3 Exitus
SA444327S2T3Serum T3 Healthy discharged
SA444328S1T3Serum T3 Healthy discharged
SA444329S4T3Serum T3 Healthy discharged
SA444330S3T3Serum T3 Healthy discharged
SA444331S6T3Serum T3 Polyneuropathic syndrome
SA444332S5T3Serum T3 Polyneuropathic syndrome
Showing results 1 to 32 of 32

Collection:

Collection ID:CO004050
Collection Summary:Serum samples (n = 32) collected retrospectively in April 2020 at regular intervals (0 (April 10, 2020), 1st (April 13, 2020), 2nd (April 17, 2020), and 3rd (April 20, 2020) time points, giving four samples per patient) and preserved at −80°C
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR004066
Treatment Summary:All samples, previously stored at −80°C, were thawed at 4°C for 1 hour prior to analysis. The samples were briefly vortexed and then centrifuged at 14,000×g for 5 minutes at 4°C. The resulting supernatants were subsequently collected for further analysis

Sample Preparation:

Sampleprep ID:SP004063
Sampleprep Summary:Each sample was prepared by adding a commercially prepared pH 7.4 sodium phosphate buffer (Bruker, Billerica, MA, USA) and serum at a 1:1 ratio, resulting in a final volume of 600 µL for each sample. Samples were then manually shaken gently for 1 min before being transferred into 5-mm SampleJet™ NMR tubes.

Analysis:

Analysis ID:AN006439
Laboratory Name:Acıbadem Labmed Clinical Laboratory NMR Center
Analysis Type:NMR
Num Factors:12
Num Metabolites:40
Units:mmol/L

NMR:

NMR ID:NM000314
Analysis ID:AN006439
Instrument Name:Bruker Avance IVDr
Instrument Type:FT-NMR
NMR Experiment Type:1D-1H
Spectrometer Frequency:600 MHz
NMR Probe:Double Resonance Broadband Probe (BBI)
NMR Solvent:H2O + D2O
NMR Tube Size:5 mm x 4 in
Shimming Method:Topshim_ivdr
Pulse Sequence:noesygppr1d
Water Suppression:NOESY
  logo